Can-Fite BioPharma vs CytoMed Therapeutics
CANF and GDTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CANF and GDTC compare
CytoMed Therapeutics grew revenue faster over the last twelve months (367% versus −39.9% for Can-Fite BioPharma).
CytoMed Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1227% compared with −2427% at Can-Fite BioPharma.
CytoMed Therapeutics scores higher on the StockData Score (4 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CANF | GDTC |
|---|---|---|
| Size and price | ||
| Share price | $1.53 | $0.783 |
| Change, 1 year | −79.3% | −60.1% |
| Change, 5 years | −99.4% | – |
| Beta (5Y) | 1.47 | −0.42 |
| Employees | 5 | 5 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −39.9% | 367% (better) |
| Revenue growth, 5Y average | −11.9% | – |
| Profitability | ||
| Operating margin | −2457% | – |
| Net margin | −2427% | −1227% (better) |
| FCF margin | −2210% | −1336% (better) |
| Return on equity | −217% | −51.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Interest coverage | −35.0× | – |
| Current ratio | 3.60 | 5.17 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Ownership | ||
| Held by institutions | 1.9% | 0.10% |
| Held by insiders | 0.00% | 25.9% |
| Insider net buying, 12 months | – | $729K |
Go deeper
- CANF stock overview
- CANF income statement
- CANF valuation and score
- GDTC stock overview
- GDTC income statement
- GDTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.